Biotargets of Cancer in Current Clinical Practice
Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets
- PDF / 12,122,386 Bytes
- 571 Pages / 504.57 x 720 pts Page_size
- 87 Downloads / 195 Views
For further volumes: http://www.springer.com/series/7632
Mauro Bologna Editor
Biotargets of Cancer in Current Clinical Practice
Editor Mauro Bologna, M.D. Department of Experimental Medicine University of L’Aquila L’Aquila, Italy
ISBN 978-1-61779-614-2 e-ISBN 978-1-61779-615-9 DOI 10.1007/978-1-61779-615-9 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2012934059 © Springer Science+Business Media, LLC 2012 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
I dedicate this work to all those from whom I learned, during my professional education path, but mostly to Pietro Ubaldo Angeletti, M.D., Professor of General Pathology at the University of L’Aquila Medical School in the 1970s and 1980s and coworker of Rita Levi Montalcini in the Nerve Growth Factor discovery, who had me in his laboratory at the beginning of my career (since 1977), as Assistant Fellow and later Professor; I learnt many fundamental aspects of research from him; I am especially in debt to him, since he acted also as my supportive mentor in following times, until his premature passing away in 1992 at age 59. Renato Dulbecco, M.D., Nobel Prize winner for Medicine, who accepted me in his laboratory for about 3 years at the Salk Institute (La Jolla, CA, USA), first when I was awarded a fellowship from Accademia dei Lincei (Rome, Italy, 1979) and later in quality of visiting research associate. I absorbed a great deal of methodology, scientific deduction and character from him. His beautiful mind passed away in february 2012 at age 98. Moreover, I dedicate this work to my family and, in particular, to my wife, Donatella, who always supported me lovingly and magnificently, and by doing so made (and still makes) all my productive efforts possible.
Preface
Biotargets of cancer are continuously evolving. Clinically valuable Biotargets are a subcategory of Biomarkers, molecules of note i
Data Loading...
